𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term treatment with long-acting risperidone in Korean patients with schizophrenia

✍ Scribed by Moon-Soo Lee; Young-Hoon Ko; Sang-Hoon Lee; Yong-Jin Seo; Seung-Hyun Kim; Sook-Haeng Joe; Chang-Su Han; Jung-Ho Lee; In-Kwa Jung

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
146 KB
Volume
21
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objectives

We evaluated the efficacy and safety of long‐acting risperidone for 48‐week period in Korean patients.

Methods

This was a non‐randomized, open‐label, single‐centered, 48‐week study. Each of the participants visited the hospital every 2 weeks, and injections were given at each visit. Complete evaluations were done on five occasions (baseline, 12, 24, 36, 48 weeks). We used Clinical Global Impression, Positive and Negative Syndrome Scale, Global Assessment of Functioning, Subjective Well‐being under Neuroleptic treatment scale and Short‐form‐36 health survey. Drug attitude inventory and Drug Induced Extra‐Pyramidal Symptoms Scale were also used.

Results

Forty patients were enrolled, and twenty‐five patients completed this study. The therapeutic response rate was 36.1% in LOCF and 48% in completer's analysis. Scores on CGI, PANSS subscales and total were significantly decreased over 48‐week period. Scores on other assessments did not show any significant changes over the period. At weeks 48, there was no significant difference in the changes of scores from baseline on self‐rated assessments between the clinical improvement and non‐improvement groups.

Conclusions

Our study showed significant improvement of investigator‐rated psychiatric symptoms in long‐term follow‐up using long‐acting risperidone. Further researches would be required to find out the effects of the psychiatric symptom improvements on overall changes in perceived functioning and well‐being. Copyright © 2006 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Long-term safety and efficacy of long-ac
Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients
✍ Werner Kissling; Per Glue; Rossella Medori; Steve Simpson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB 👁 1 views

## Abstract This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot a

Efficacy and safety of long-acting rispe
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder
✍ Robert A. Lasser; Cynthia A. Bossie; Young Zhu; Georges Gharabawi; Mariëlle Eerd 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi

Remission in schizophrenia: one-year Ita
Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder
✍ Alessandro Rossi; Anna Bagalà; Vincenzo Del Curatolo; Francesco Scapati; Micaela 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 155 KB 👁 1 views

## Abstract ## Objectives To evaluate the maintenance of efficacy of risperidone long‐acting injectable (RLAI) in stable patients with schizophrenia or schizoaffective disorders. The prevalence of patients who met standardized remission criteria will be also evaluated as well as the predictors fac

Effects of switching to long-acting inje
Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia
✍ Sung-Wan Kim; Il-Seon Shin; Jae-Min Kim; Seung-Hyun Lee; Yo-Han Lee; Su-Jin Yang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## Abstract ## Objective To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long‐acting injectable risperidone (LAIR) in patients with schizophrenia. ## Methods Thirty‐six patients with schizophrenia treated with oral

Quetiapine is effective against anxiety
Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia
✍ Siegfried Kasper 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

This analysis of data from the open-label extension (OLE) phases of three randomized clinical trials of quetiapine in patients with schizophrenia (n=415) was undertaken to investigate whether the initial improvements in anxiety and depressive symptoms were maintained during long-term treatment. The